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SUMMARY
Caspase-2 is an evolutionarily conserved caspase, yet its biological function and cleavage targets
are poorly understood. Caspase-2 is activated by the p53 target gene product PIDD (also known as
LRDD) in a complex called the Caspase-2-PIDDosome. We show that PIDD expression promotes
growth arrest and chemotherapy resistance by a mechanism that depends on Caspase-2 and wild-
type p53. PIDD-induced Caspase-2 directly cleaves the E3 ubiquitin ligase Mdm2 at Asp 367,
leading to loss of the C-terminal RING domain responsible for p53 ubiquitination. As a
consequence, N-terminally truncated Mdm2 binds p53 and promotes its stability. Upon DNA
damage, p53 induction of the Caspase-2-PIDDosome creates a positive feedback loop that inhibits
Mdm2 and reinforces p53 stability and activity, contributing to cell survival and drug resistance.
These data establish Mdm2 as a cleavage target of Caspase-2 and provide insight into a
mechanism of Mdm2 inhibition that impacts p53 dynamics upon genotoxic stress.
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INTRODUCTION
The tumor suppressor function of p53 is dysregulated in the vast majority of human cancers
via genomic loss, point mutation or alterations in signaling components upstream of p53,
such as ARF loss or Mdm2 amplification. As a transcription factor, p53 responds to cellular
stress by inducing target genes that promote cell cycle arrest, DNA repair, apoptosis or
senescence (Horn and Vousden, 2007; Menendez et al., 2009; Vousden, 2006). Because p53
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plays a central role in determining cell fate decisions, elucidating the signaling circuitry that
governs p53 function is critical for understanding tumorigenesis and manipulating p53 for
therapeutic purposes.
Many factors regulate the stability and activity of p53 such as posttranslational
modifications, protein-protein interactions and subcellular localization (Manfredi, 2010;
Marine and Lozano, 2010). The E3 ubiquitin ligase mouse/human double minute 2 (Mdm2/
Hdm2) is a master regulator of p53 (Kruse and Gu, 2009; Marine and Lozano, 2010). Mdm2
controls p53 levels by targeting it for ubiquitin-mediated proteasomal degradation (Haupt et
al., 1997; Kubbutat et al., 1997) and can bind p53 and inhibit its transcriptional activity
(Momand et al., 1992). Mdm2 is also a target gene of p53, establishing a negative feedback
loop that inhibits p53 activity following DNA damage (Juven et al., 1993; Wu et al., 1993).
Both positive and negative feedback loops are prominent features of the autoregulation of
the p53 pathway (Harris and Levine, 2005; Lu, 2010). Well known examples are the
negative feedback loops induced by the p53 target gene products Mdm2, Wip1, Pirh2 and
Cop1 (Marine and Lozano, 2010). However, p53 target genes that function in positive
feedback loops have also been identified. For example, the p53 target protein Wig-1
(ZMAT3) has been shown to increase p53 levels by enhancing p53 mRNA stability (Vilborg
et al., 2009), while 14-3-3 sigma inhibits Mdm2-mediated ubiquitination of p53 (Yang et al.,
2003). Studies in single cells and mouse models have demonstrated that p53 activity is
induced in oscillations or pulses, both in response to high levels of damage and during the
cell cycle of normal unstressed cells (Batchelor et al., 2009; Hamstra et al., 2006; Loewer et
al., 2010). Given the pulsatile dynamics of p53 signaling (Lahav et al., 2004), it may be
essential that p53 induces its own negative and positive regulators that control, or are
controlled by, the p53 response and ultimately define p53 activity.
The p53 target gene, leucine-rich repeats and death domain containing (Lrdd), also known
as p53-induced protein with a death domain (Pidd), functions in apoptosis, NF-κB-mediated
survival signaling, cell cycle arrest, DNA repair and drug resistance (Janssens et al., 2005;
Lin et al., 2000; Logette et al., 2011; Oliver et al., 2010; Tinel and Tschopp, 2004). PIDD is
a death domain protein that is autocatalytically cleaved into multiple fragments generating
PIDD-C and PIDD-CC (Tinel et al., 2007). PIDD-C is a component of the so-called
PIDDosome complex with RIP1 and Nemo, which promotes cell survival via NF-κB
activation (Janssens et al., 2005). PIDD-CC activates the protease Caspase-2 in a
cytoplasmic PIDDosome complex assembled by the adaptor protein, RAIDD/CRADD
(Bouchier-Hayes et al., 2009; Park et al., 2007; Tinel and Tschopp, 2004). We recently
discovered that Pidd is induced in murine chemo-resistant tumors in vivo and can promote
cell cycle arrest and drug resistance in human lung cancer cells (Oliver et al., 2010). The
mechanism by which PIDD promotes cell cycle arrest and drug resistance is unknown.
Caspase-2 is an evolutionarily conserved caspase with features of both initiator and
executioner caspases, yet very few of its targets are known (Krumschnabel et al., 2009a;
Krumschnabel et al., 2009b; Kumar, 2009; Vakifahmetoglu-Norberg and Zhivotovsky,
2010). For example, Caspase-2 cleaves Golgin-160, and this cleavage has been implicated in
Golgi disintegration and the initiation of apoptosis (Mancini et al., 2000). Caspase-2-
mediated cleavage of Bid has been shown to promote cytochrome c release at the
mitochondria during apoptosis (Guo et al., 2002; Upton et al., 2008). Additionally,
Caspase-2 has been proposed to cleave RIP1 leading to NF-κB inhibition (Guha et al.,
2010). Despite early evidence suggesting Caspase-2 plays a role in apoptosis, its function in
this process remains controversial. Caspase-2 null mice are viable, fertile, and display only
mild defects in apoptosis (Bergeron et al., 1998). Caspase-2 can also influence cell cycle
regulation and DNA repair (Kumar, 2009). Recently, Caspase-2 has been implicated as a
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tumor suppressor gene as caspase-2 null mouse embryo fibroblasts (MEFs) exhibit
increased proliferation and enhanced sensitivity to transformation (Ho et al., 2009). Tumor
formation was accelerated in caspase-2 null mice in a Eμ-myc model of lymphoma (Ho et
al., 2009). Identification of new Caspase-2 cleavage targets should shed light on its
biological functions.
Here we demonstrate that DNA damage and PIDD-induced activation of Caspase-2 trigger
cleavage of Mdm2, which reinforces p53 stability and activity in a positive feedback loop.
This signaling pathway provides a mechanistic explanation for how transiently increased
PIDD expression can protect cells from DNA damage.
RESULTS
PIDD positively regulates p53 levels
The PIDD promoter contains a non-canonical p53 response element and is induced upon
DNA damage and p53 activation (Jordan et al., 2008; Lin et al., 2000). We verified that
PIDD is increased upon DNA damage by treating human non-small cell lung cancer
(NSCLC) cell lines with a standard-of-care chemotherapy agent cisplatin. Consistent with
published data, PIDD was highly induced in p53 wild-type cells and much less so, or not at
all, in p53-null and mutant cells (Supp Fig S1A). We next took advantage of a unique mouse
model system that allows restoration of endogenous p53 to physiological levels (Ventura et
al., 2007). Homozygous p53-Lox-Stop-Lox (LSL) mice (p53LSL/LSL) crossed to
ROSA26CreERT2 mice are functionally p53 null until addition of 4-hydroxytamoxifen (4-
OHT), which activates Cre recombinase. Cre excises the Stop cassette and restores the p53
locus to its wild-type state. Three independent mouse lung tumor cell lines driven by
oncogenic KrasG12D (KrasLA/+;p53LSL/LSL;ROSA26CreERT2) were treated with vehicle or 4-
OHT and analyzed at multiple time points (Feldser et al.). Restoration of p53 led to p21
induction and G1 cell cycle arrest (Supp Fig S1B–C). Pidd expression was significantly
induced from 5–15-fold as early as 24 hrs (Fig 1A). Thus, Pidd is induced both upon DNA
damage as previously described and upon physiologically relevant p53 restoration in cancer
cells.
To examine the consequences of PIDD expression, we overexpressed Flag-tagged PIDD in
human NSCLC cell lines that harbored KRAS mutations and were either p53 wild-type, null
or carrying point mutant alleles of p53. PIDD expression was confirmed in the nuclear and
cytoplasmic fractions of nine independent cell lines (SuppFig S1D and data not shown).
Exogenous PIDD expression led to a slower growth rate and G1 arrest in p53 wild-type cells
as we previously described (Oliver et al., 2010). Surprisingly, PIDD did not induce growth
arrest in p53 null or mutant cells (Fig 1B). We previously found that p53 wild-type PIDD-
expressing cells showed significantly increased cisplatin resistance compared to vector
control cells (Oliver et al., 2010). In contrast, p53 null or mutant PIDD-expressing cells did
not exhibit increased cisplatin resistance, as indicated by a lack of change in the IC50 of
PIDD-expressing versus control cells (Fig 1C). Thus, drug response in PIDD-expressing
cells was significantly associated with p53 status. Of nine cell lines, the one exception was
the p53 wild-type line, A427, in which PIDD overexpression did not induce cell cycle arrest
or cisplatin resistance (see explanation in Supp Fig S1D). Taken together, these data suggest
that PIDD expression promotes cell cycle arrest and drug resistance in a p53-dependent
manner.
To test the requirement of p53 for PIDD-induced cell cycle arrest, we compared cell growth
rates in p53 wild-type HCT116 colon cancer cells and isogenic p53 null derivatives.
Expression of PIDD significantly reduced cell growth rate in p53 wild-type cells (p < 0.02)
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and had no effect in the absence of p53 (p > 0.38) (Fig 1D), demonstrating that p53 is
required for PIDD-induced inhibition of the cell cycle.
To further investigate the relationship between PIDD and p53, we analyzed p53 protein
levels in control and PIDD-expressing cells. In p53 wild-type cells, PIDD expression led to
increased nuclear p53 levels and an increase in nuclear p21, a canonical p53 target (Fig 1E).
Levels of p53 and p21 protein did not change in p53 null or mutant cells upon PIDD
expression (Supp Fig S1E). In p53 wild-type cells, p53 mRNA levels were unchanged upon
PIDD expression while p21 mRNA was upregulated in a p53-dependent manner (Fig 1F),
suggesting that PIDD leads to increased p53 protein stability and activity. Thus, PIDD, a
target gene product of p53, can increase p53 protein levels in a positive feedback mode.
PIDD-induced growth arrest and cisplatin resistance depend on Caspase-2
The Caspase-2-PIDDosome is a high molecular weight complex composed of PIDD, the
adaptor protein, RAIDD, and Caspase-2 (Tinel and Tschopp, 2004). This complex is
assembled via death domain interactions between PIDD and RAIDD. RAIDD recruits
Caspase-2 via their mutual caspase recruitment domains (CARDs) (Park et al., 2007).
Formation of the PIDDosome activates Caspase-2 by proximity-induced dimerization and
subsequent autoprocessing of pro-Caspase-2 (Bouchier-Hayes et al., 2009). We found that
cytoplasmic pro-Caspase-2 was significantly reduced or absent in all cell lines upon ectopic
PIDD expression, regardless of p53 status (Fig 2A). Under different lysis conditions, the
cleavage products of Caspase-2 that are generated during activation are detectable in total
cell lysates as well (Supp Fig 2A). Transcriptional repression of CASP2 by p53 (Baptiste-
Okoh et al., 2008) is not likely under these conditions since the reduction of pro-Caspase-2
by ectopic PIDD expression occurred independently of p53 status (Fig 2A) and CASP2
mRNA was not dramatically affected by PIDD expression (Fig 2B). Previous studies have
demonstrated that Caspase-2 cleavage is not required for its full activation (Baliga et al.,
2004) and cleavage does not necessarily imply activation (Bouchier-Hayes et al., 2009).
These results are consistent, however, with previous studies demonstrating PIDD's ability to
promote Caspase-2 activation. Importantly, PIDD expression did not increase cleavage of
PARP or Caspase-3 (Fig 1E, Supp Fig S1D and data not shown), suggesting that PIDD
expression does not promote apoptosis under these conditions.
Given that PIDD is autocatalytically cleaved into multiple fragments that have been
implicated in a variety of responses to cellular stress, we sought to determine which
fragment(s) contribute to cell cycle arrest and drug resistance. Point-mutant versions of
PIDD were stably expressed in human lung cancer cells that generate either PIDD-C
(F582A), PIDD-CC (S446A) or full-length PIDD (S466A/F582A) as previously described
(Tinel et al., 2007). Expression of both PIDD-CC and full-length PIDD induced growth
arrest and cisplatin resistance in p53 wild-type cells similar to wild-type PIDD, but PIDD-C
did not (Fig 2CD and data not shown). This suggests that PIDD-C, involved in NF-κB-
mediated survival signaling, is not required for cell cycle arrest and resistance. Expression of
PIDD-CC, which has been implicated in Caspase-2 activation, was sufficient to promote cell
cycle arrest and drug resistance. Moreover, growth arrest and drug resistance correlated with
the level of Caspase-2 cleavage (Fig 2D and data not shown), suggesting that Caspase-2
activation may be an important determinant of PIDD-induced cell cycle arrest and drug
resistance. To test this directly, we infected cells with Caspase-2 shRNAs or controls and
subsequently infected them with PIDD or controls. Caspase-2 knockdown was incomplete,
but enhanced cell growth rate compared to control cells, similar to recent studies implicating
Caspase-2 as a tumor suppressor (Ho et al., 2009). Importantly, reducing Caspase-2 levels
partially rescued the growth rate of cells expressing PIDD (Fig 2E), suggesting that
Caspase-2 is required for PIDD-induced cell cycle arrest.
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The Caspase-2-PIDDosome promotes Mdm2 cleavage
We hypothesized that the Caspase-2-PIDDosome may act to increase p53 levels by
inhibiting Mdm2, a key negative regulator of p53. To address this, we analyzed Mdm2
expression in three NSCLC lines with or without PIDD expression. Low levels of full-length
Mdm2 (~90 kDa) were present in all lines and did not dramatically differ in control versus
PIDD-expressing cells (Fig 3A). Strikingly, however, a ~60 kDa Mdm2 species (referred to
hereafter as p60) was highly enriched in PIDD-expressing cells compared to controls in all
lines examined (Fig 3A). The Mdm2 p60 product could represent an alternative splice
variant or cleavage product of Mdm2. Mdm2 p60 was detected using an N-terminal
antibody, whereas two independent C-terminal Mdm2 antibodies detected a 25–30 kDa
fragment (Fig 3A and data not shown) but did not detect p60. Thus, p60 appeared to be an
N-terminal fragment of Mdm2. Consistent with this, relative levels of p60 and p25
fragments correlated well in all cell lines examined. The N-terminal fragment of Mdm2 was
detected in the nucleus and cytoplasm of PIDD-expressing cells, whereas the p25 C-terminal
fragment was found exclusively in the cytoplasm (Fig 3A). The N-terminal region of Mdm2
contains a nuclear localization sequence and nuclear export signal, whereas the C-terminal
region does not (Coutts et al., 2009), consistent with the hypothesis that Mdm2 is cleaved in
the cytoplasm and the p60 fragment enters the nucleus.
Mdm2 contains a well-conserved caspase cleavage site, Asp-Val-Pro-Asp (DVPD), at which
cleavage generates an ~60 kDa N-terminal product (Pochampally et al., 1998). This site is
conserved among human, mouse and hamster (Chen et al., 1997; Pochampally et al., 1998).
Upon re-examination of Mdm2 orthologs with recently annotated sequence data, we found
that the DVPD site is also conserved in zebrafish mdm2 (Fig 3B). Previous studies
demonstrated that activation of a temperature-sensitive p53 leads to Mdm2 cleavage at
DVPD via a Caspase-3-like activity (Pochampally et al., 1999). This suggested to us that
Caspase-2 might be the p53-induced caspase responsible for Mdm2 cleavage.
To test whether Mdm2 is cleaved at the DVPD site by Caspase-2, we mutated D367 to
alanine (D367A) or glutamic acid (D367E) with vectors containing full-length N-terminal
Myc-tagged human Mdm2 (Zhang et al., 2003). We also generated a truncated Mdm2 p60
by introducing a STOP codon following the DVPD site. Full-length Mdm2 (WT), D367A,
D367E, p60, or eGFP control vectors were transiently expressed in 293T cells, and nuclear
and cytoplasmic fractions were immunoblotted with anti-Myc-tag antibodies. Expression of
wild-type Mdm2 led to appearance of the full-length Mdm2 protein as well as low levels of
p60 products (Fig 3C). Expression of D367A and D367E eliminated expression of the p60
products. Importantly, transiently-expressed Mdm2 p60 migrated at the same size as the
cleavage products that were present upon wild-type Mdm2 expression (Fig 3C). Since
Mdm2 contains an internal alternative start codon at amino acid 50, two full-length and two
cleavage products were present, migrating as a doublet. Similar results were observed using
A549 cells (data not shown). These data suggest that Mdm2 is cleaved at D367, generating a
p60 protein doublet consistent with previous studies (Pochampally et al., 1998).
To test whether PIDD expression can promote Mdm2 cleavage, we expressed PIDD in 293T
cells in the presence or absence of Myc-tagged Mdm2. PIDD expression caused a decrease
in full-length Mdm2 and an increase in cleaved Mdm2, enhancing the ratio of cleaved to
full-length Mdm2 (Fig 3D). Expression of PIDD and RAIDD are known to promote
formation of the PIDDosome and subsequent Caspase-2 activation (Kitevska et al., 2009). If
the Caspase-2-PIDDosome was responsible for Mdm2 cleavage, then expression of RAIDD
might also promote Mdm2 cleavage. Indeed, expression of RAIDD was sufficient to
promote cleavage of wild-type, but not point mutant D367A Mdm2 (Fig 3E) whereas Nemo
did not promote Mdm2 cleavage (Supp Fig S3A). We next tested whether activated
Caspase-2 could promote Mdm2 cleavage. Expression vectors for truncated constitutively-
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active (C2) or catalytically-dead (C320A) Caspase-2 (Guha et al., 2010) were co-transfected
with wild-type or D367A Mdm2. Expression of Caspase-2, but not C320A, led to a striking
disappearance of full-length Mdm2 and the generation of cleaved Mdm2 p60 (Fig 3F).
Mutation of D367 to alanine completely abolished Mdm2 cleavage. Together, these data are
fully consistent with a model in which formation of the Caspase-2-PIDDosome promotes
Mdm2 cleavage.
Caspase-2 cleaves Mdm2 in vitro
Given that the Caspase-2 could activate another caspase (such as Caspase-3) responsible for
Mdm2 cleavage, we tested directly whether recombinant Caspase-2 could cleave Mdm2.
Wild-type or D367A Mdm2 were transiently expressed in 293T cells followed by
immunoprecipitation (IP) with anti-Myc-tag antibodies. The Mdm2 IPs were incubated
alone or with recombinant Caspase-2 (C2) or Caspase-3 (C3), and then subjected to
immunoblotting with Mdm2 N-terminal or C-terminal antibodies. Full-length Mdm2 (~p90)
was entirely absent in the reactions with Caspase-2, and Mdm2 was partially cleaved by
Caspase-3 as previously described (Fig 4A). In the presence of both caspases, we detected
increased p60 fragments using N-terminal antibodies, and increased p30 fragments using C-
terminal antibodies (Fig 4A). Cleavage likely occurred at the DVPD site, as the D367A
mutant was not cleaved by either caspase. Recombinant Caspase-2 and -3 were also able to
cleave recombinant Mdm2 (Fig 4B), demonstrating that both Caspase-2 and -3 can cleave
Mdm2 in vitro. Importantly, given that Caspase-3 activity is not detectable in cells under the
growth arrest conditions induced by PIDD in our experimental conditions, these results
suggest that activated Caspase-2 directly cleaves Mdm2 following PIDDosome activation.
Low levels of exogenous Mdm2 p60 were present in 293T cells without addition of
exogenous Caspase-2 (see Fig 3C, WT lane), so it was possible that basal Caspase-2 activity
was present in these cells. Thus, we co-transfected Mdm2 with retroviral vectors carrying
control or Caspase-2 shRNAs and examined Mdm2 expression. Caspase-2 knockdown was
incomplete but significantly reduced the level of Mdm2 p60 (Fig 4C). To test whether
Caspase-2 knockdown was sufficient to reduce cleavage of endogenous Mdm2, we stably
infected A549 cells with retroviral vectors carrying Caspase-2 shRNAs or controls. Again
Caspase-2 knockdown was not complete, but reduction of Caspase-2 significantly inhibited
cleavage of endogenous Mdm2 (Fig 4D). Expression of Caspase-2 shRNAs had no effect on
pro-Caspase-3, 6, 8 or 9 levels (Fig 4CD and data not shown). These data demonstrate that
Caspase-2 cleaves Mdm2 in vitro and in human cancer cells. Furthermore, knockdown of
Caspase-2 in PIDD-expressing cells reduced Mdm2 cleavage and nuclear p53, suggesting
that Caspase-2 is required for Mdm2 cleavage and subsequent p53 accumulation (Fig 4E).
Cleaved Mdm2 binds p53 and promotes p53 stabilization
The N-terminus of Mdm2 harbors a well-characterized p53 binding domain (Chen et al.,
1993). Upon cleavage at D367, the p53-binding domain is dissociated from the C-terminal
ubiquitin-conjugating RING finger domain. Truncated forms of Mdm2 fail to target p53 for
degradation and consequently lead to elevated p53 levels (Honda and Yasuda, 2000;
Kubbutat et al., 1997; Pochampally et al., 1999). To determine whether Mdm2 p60 binds
p53 in cells, p53 was immunoprecipitated from A549 cells expressing PIDD or vector
control. As expected, PIDD-expressing cells had increased levels of p53 and Mdm2
cleavage compared to controls (Fig 5A, left). Western blotting of the p53 IPs with antibodies
to Mdm2 (N-terminal and C-terminal) revealed that full-length and Mdm2 p60 were both
bound to p53 in the presence of PIDD and that p60 was bound at higher levels than full-
length Mdm2 (Fig 5A, right). Both antibodies revealed that significantly less full-length
Mdm2 was bound to p53 in PIDD-expressing cells compared to control cells.
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Because Mdm2 p60 lacks the RING domain, it should fail to promote p53 modifications
such as ubiquitination, sumoylation and neddylation. Loss of the RING finger domain may
also contribute to increased Mdm2 p60 stability due to decreased auto-ubiquitination (Honda
and Yasuda, 2000). To determine the effects of Mdm2 p60 on p53, we expressed wild-type
(WT), non-cleavable (D367A), RING finger domain mutant (C464A) and truncated Mdm2
(p60) in 293T cells and analyzed p53 levels. Wild-type and non-cleavable Mdm2 caused a
dramatic increase in p53 modifications (Fig 5B), whereas Mdm2 C464A (Supp Fig S4A)
and Mdm2 p60 (Fig 5B) did not. We tested whether Mdm2 p60 could compete for
interaction with p53 and inhibit p53 modification by full-length Mdm2. Each Mdm2
construct was expressed alone (WT, D367A, or p60) or in combination with p60 in 293T
cells. Co-expression of Mdm2 p60 with either wild-type or D367A Mdm2 dramatically
reduced p53 modifications (Fig 5B). In p53 wild-type U2OS cells, exogenous expression of
wild-type and D367A Mdm2 led to slightly reduced p53 levels, whereas Mdm2 p60
expression caused a significant increase in p53 levels (Fig 5C). Increased p53 levels in the
presence of Mdm2 p60 were also associated with a reduction in p53 modifications (Supp Fig
S4B). Together these data suggest that the Mdm2 p60 fragment promotes the stabilization of
p53 by reducing p53 modifications, most likely ubiquitination and subsequent proteasomal-
mediated degradation.
To further examine whether Mdm2 cleavage inhibits p53 modifications, we co-expressed
either constitutively active (Casp2) or catalytically dead (C320A) Caspase-2 along with
wild-type Mdm2 in 293T cells. Consistent with previous results, p53 modifications were
completely inhibited by expression of active Caspase-2 but not by catalytically dead
Caspase-2 (Fig 5D) or Nemo (see Supp Fig S3A). Similar results were obtained in U2OS
cells (data not shown). Expression of RAIDD, which promotes Mdm2 cleavage (Fig 3E),
also inhibited p53 modification in the presence of wild-type but not D367A Mdm2 (Supp
Fig S4C). These results suggest that activation of the Caspase-2-PIDDosome leads to Mdm2
cleavage by Caspase-2, thereby inhibiting Mdm2 and promoting p53 stability.
Caspase-2-PIDDosome cleaves Mdm2 in response to DNA damage
Given that p53 induces PIDD, which activates Caspase-2 and promotes Mdm2 cleavage, we
reasoned that p53 activation should promote Mdm2 cleavage in response to DNA damage.
We treated U2OS osteosarcoma cells with increasing doses of doxorubicin (dox) and
analyzed Mdm2 and p53 levels. Dox treatment led to increased total Mdm2 levels with
corresponding increases in cleaved Mdm2 that were maximal at 0.5 μM and diminished at
higher doses. Levels of p53 also peaked at 0.5 μM (Supp Fig S5A). To assess the role of the
Caspase-2 in Mdm2 cleavage, we infected p53 wild-type U2OS and A549 cells with
retroviral vectors carrying Caspase-2 or control shRNAs and then damaged cells with dox.
In both cell types, dox treatment caused Mdm2 cleavage that increased with damage (0–0.5
μM) (Fig 6AB). Caspase-2 knockdown did not affect pro-Caspase-3 levels, but significantly
reduced cleaved Mdm2 at the basal level and upon damage, suggesting that the Mdm2
cleavage products are generated in a Caspase-2-dependent manner (Fig 6AB).
To determine whether the Caspase-2-PIDDosome was required for Mdm2 cleavage, we
tested whether inhibition of PIDD or RAIDD impacted Mdm2 cleavage upon DNA damage.
PIDD and RAIDD knockdown in U2OS cells did not affect Caspase-3 levels (Fig 6CD).
Cells were then damaged with 0.5 μM of dox, a concentration that induces PIDD expression
and Mdm2 cleavage (Supp Fig S5AB), and Mdm2 levels were assessed in cytoplasmic
fractions by western blotting. Importantly, inhibition of PIDD or RAIDD had no effect on
pro-Caspase-3, but resulted in a striking reduction in Mdm2 cleavage compared to control
siRNAs (Fig 6E). Finally, we compared Mdm2 cleavage in the presence or absence of
siRNAs to Caspase-2 or -3. Knockdown of Caspase-2, but not Caspase-3, significantly
reduced Mdm2 p60 products (Fig 6F). Treatment with the double-strand break-inducing
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agent, neocarzinostatin, also caused Mdm2 cleavage, which was abolished by Caspase-2-
PIDDosome inhibition (Supp Fig S5C). These data demonstrate that DNA damage activates
the Caspase-2-PIDDosome, leading to Caspase-2-mediated cleavage and inhibition of
Mdm2.
The Caspase-2-PIDDosome impacts p53 dynamics during the DNA damage response
Inhibition of Mdm2 cleavage would be predicted to result in increased total Mdm2 and
decreased p53 levels. To test this, we knocked down Caspase-2 or PIDD and damaged cells
with dox. As predicted, p53 levels were slightly reduced at the basal level upon Caspase-2
and PIDD knockdown (Fig 7AB). Upon DNA damage, p53 levels recovered, and
subsequently peaked earlier than control cells (e.g. 20 hrs), followed by a dramatic decline
in levels at 26 hrs. This suggests that Mdm2 cleavage is not required for the initial
accumulation of p53, but appears to impact the maintenance of p53 levels following DNA
damage.
To assess the impact of the Caspase-2-PIDDosome on the recovery of cells following DNA
damage, cells were treated with dox for 8 hrs, washed and allowed to recover. In control
cells, p53 levels peaked by 24 hrs. In cells with Caspase-2 or PIDD knockdown, p53 levels
were induced to a similar extent, but peaked earlier and declined prematurely after 32 hrs
(Fig 7ABC and Supp Fig S6AB). Similar results were obtained in cells synchronized with
hydroxyurea (data not shown). Together, this suggests that the Caspase-2-PIDDosome is an
important factor in maintaining p53 levels and regulating p53 dynamics following DNA
damage.
Because PIDD expression promoted resistance to DNA damage in p53 wild-type cells (Fig
1C), we sought to determine whether inhibition of PIDD would sensitize to DNA damage.
We treated cells with control or PIDD siRNAs and measured apoptosis by flow cytometry
following dox treatment. PIDD inhibition resulted in a significant increase in the percentage
of apoptotic and dead cells compared to controls (Fig 7D). Together, these data suggest that
Mdm2 cleavage by the Caspase-2-PIDDosome establishes a positive feedback loop induced
by p53 that reinforces p53 stability and activity following DNA damage (Fig 7E).
DISCUSSION
Here we show that activation of the Caspase-2-PIDDosome promotes cleavage of Mdm2.
Caspase-2 directly cleaves Mdm2 in a conserved DVPD367 site, leading to separation of the
p53 binding domain and the RING finger responsible for p53 ubiquitination. As a result,
Mdm2 cleavage inhibits its E3 ubiquitin ligase activity, leading to increased p53 levels and
activity. We show that Mdm2 cleavage in human lung cancer cells promotes p53-dependent
cell cycle arrest and subsequent drug resistance. Furthermore, Mdm2 cleavage by the
Caspase-2-PIDDosome occurs in response to DNA damage and contributes to the
maintenance of p53 levels. Together, p53 activation of the Caspase-2-PIDDosome
establishes a positive feedback loop that promotes p53 stability and activity following DNA
damage (Fig 7E).
Previous studies showed that Mdm2 is cleaved by a caspase-3-like activity under apoptotic
and non-apoptoptic, growth arrest conditions (Chen et al., 1997; Erhardt et al., 1997;
Pochampally et al., 1999; Pochampally et al., 1998). The caspase responsible for Mdm2
cleavage was p53-inducible (Pochampally et al., 1999) and distinct from Caspases 1, 3, 6, 7
and 8 (Erhardt et al., 1997; Pochampally et al., 1999; Pochampally et al., 1998). Thus, the
identity of the caspase that directly cleaved Mdm2 and its mechanism of induction by p53
remained unknown. Our studies resolve these issues by demonstrating that 1) Caspase-2
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directly cleaves Mdm2 and 2) the mechanism of Caspase-2 activation is due to p53-
mediated induction of PIDD.
Very few Caspase-2 cleavage targets are known, making its biological role elusive.
Interestingly, the Caspase-2 cleavage site identified here in Mdm2 (DVPD) is highly
conserved among vertebrates and similar to the known Caspase-2 cleavage site, ESPD, of
Golgin-160 (Mancini et al., 2000). Although studied here in the context of DNA damage and
p53 activation, we speculate that this pathway may be important for p53 regulation more
broadly. Recent studies by Ho et al. have implicated Caspase-2 as a tumor suppressor, and
the authors noted that p53 activity is reduced in caspase-2 null MEFs. This phenotype is
consistent with our model in which Caspase-2 depletion reduces Mdm2 cleavage, thus
permitting increased expression of full-length Mdm2 and enhanced degradation of p53.
Consistent with Ho et al., we observe that Caspase-2 knockdown accelerates cell growth and
results in reduced p53 and p21 levels (data not shown).
In contrast to our findings, previous studies implicated Caspase-2 in heat shock-induced
apoptosis and failed to detect Caspase-2 activation upon other types of genotoxic stress (Tu
et al., 2006). Because these studies were performed in T cells and splenocytes, it remains
possible that cell-type specific differences explain this discrepancy. We initially tested the
effects of PIDD in response to cisplatin in lung cancer cells, but began to use U2OS cells for
their ease of manipulation for siRNA and cDNA transfections. We tested doxorubicin on
U2OS cells, as it is a comment therapeutic agent for osteosarcoma and subsequently
confirmed that doxorubicin and neocarzinostatin, a double-strand break inducer, also affect
Mdm2 cleavage in lung cancer cells (Fig. 6A and Supp Fig S5C).
Mdm2 contains other potential caspase cleavage sites located N-terminal to the DVPD site.
Because Caspase-3 can cleave Mdm2 at high levels, it is possible that Caspase-2 initially
cleaves Mdm2 under low levels of DNA damage, while excessive damage activates
Caspase-3, leading to complete degradation of Mdm2 via additional cleavage sites. Recent
studies have identified a mechanism of Mdm2 degradation involving phosphorylation by
casein kinase 1 and subsequent β-TRCP-mediated destruction (Inuzuka et al., 2010). The
levels of DNA damage used in our experiments promote growth arrest and did not lead to
complete degradation of Mdm2. However, upon higher levels of damage, we observed a
reduction in full-length and cleaved Mdm2 (Supp Fig S5A). Therefore, we hypothesize that
the mode of Mdm2 regulation identified here is particularly important under reparable levels
of DNA damage.
Mdm2 interaction with p53 has been shown to inhibit p53-transcriptional activity in vitro,
but genetically-engineered mouse models have led to uncertainty about the in vivo relevance
of these findings (Itahana et al., 2007). Itahana et al. demonstrated that Mdm2 C462A
mutant mice, in which Mdm2 lacks ubiquitin-conjugation function but retains p53-binding
capacity, are embryonic lethal, similar to Mdm2 null mice. Embryonic lethality of Mdm2
C462A mice is rescued by p53 loss indicating that Mdm2 binding to p53 is not sufficient to
inhibit p53 in vivo (Itahana et al., 2007). Therefore, it may not be surprising that in the
presence of Mdm2 p60 we find stabilized p53 that appears to be transcriptionally active and
capable of inducing p21 and other p53 target genes (data not shown). How Mdm2 cleavage
ultimately impacts the transcriptional program induced by p53 is an interesting avenue of
further investigation.
Mdm2 cleavage in human lung cancer cells led to p21 induction and cell cycle arrest. We
hypothesize that this mechanism of transient Mdm2 inhibition could serve to protect p53
wild-type tumors treated with chemotherapy, if enhanced p53 preferentially induces cell
cycle arrest and/or DNA damage repair. Consistent with this hypothesis, we recently
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observed that Pidd is more highly induced in cisplatin-resistant tumors compared to naïve
tumors in response to chemotherapy in vivo (Oliver et al., 2010), suggesting that p53 may
promote arrest or repair in this context. Given that context-specific post-translational
modifications of p53 may also regulate its activity, it remains possible that p53 stability may
promote functions other than growth arrest such as apoptosis, senescence or autophagy
under different cellular conditions.
Mdm2 can bind a number of important proteins via its N-terminal and central acidic
domains, such as Rb and ARF, and can regulate the activity of other proteins by
ubiquitination (Coutts et al., 2009). Therefore, Mdm2 cleavage by Caspase-2 may have
important consequences for the regulation of a variety of p53-dependent and -independent
processes. Importantly, Mdm2 binds the Mdm2 homolog, MdmX, through their C-terminal
RING domains (Tanimura et al., 1999). Thus, Mdm2 cleavage is predicted to abolish
interaction with MdmX. The DVPD cleavage site in Mdm2 is also conserved in MdmX
(Pochampally et al., 1998), but we do not detect MdmX cleavage under these conditions
(Supp Fig S5D). MdmX is detected largely in the nucleus of human lung cancer cell lines,
which may preclude efficient interaction with Caspase-2 in the cytoplasm (Supp Fig S5D).
In either case, cleavage of MdmX and/or Mdm2 at DVPD would be expected to abolish
Mdm2/MdmX heterodimer formation (Wade et al., 2010) and prevent Mdm2-mediated
ubiquitination of p53. While our studies did not preclude that Mdm2 also inhibits the
sumoylation and neddylation of p53, ubiquitination of p53 is known to control its levels,
whereas sumoylation and neddylation have not been implicated in p53 stability, suggesting
these modifications are most likely ubiquitin (Dei and Gu, Trends in Mol Med, 2010).
Mdm2 has been shown to degrade MdmX upon DNA damage (de Graaf et al., 2003; Pan
and Chen, 2003), suggesting that cleaved Mdm2 p60 could enhance MdmX levels and
counter p53 activity. Inhibition of the Caspase-2-PIDDosome upon DNA damage did not
appear to enhance MdmX degradation in the assays used here (data not shown).
Many p53 autoregulatory loops impinge on Mdm2 (Harris and Levine, 2005; Lu, 2010) and
regulate Mdm2 by a variety of mechanisms, including interaction with MdmX, auto-
ubiquitination, phosphorylation, and here, cleavage (Wade et al., 2010). We observe that
inhibition of the Caspase-2-PIDDosome does not prevent p53 induction upon DNA damage,
but impacts the dynamics of p53 levels over time. During the past decade, it has become
appreciated that p53 exhibits pulsatile dynamics in response to DNA damage (Batchelor et
al., 2008; Lahav et al., 2004; Loewer et al., 2010). We speculate that the p53-Caspase-2-
PIDDosome-Mdm2 pathway identified here may contribute to p53 pulses during DNA
damage, by shutting down Mdm2 activity and re-establishing p53 activity. This positive
feedback loop initiated by p53-induction of PIDD may thus serve as an important
counterbalance to p53-induction of Mdm2. Together, these findings highlight the complexity
of the feedback loops dictating p53 response, and undoubtedly contribute to the cell's ability
to control p53 with exquisite sensitivity.
EXPERIMENTAL PROCEDURES
Cell lines, antibodies, constructs and reagents
Human NSCLC lines were kindly provided by Jeffrey Settleman or obtained from ATCC.
A427, A549, SW1573, H23, H1944 and H2009 cell lines were maintained in DMEM. H460,
COR-L23 and Calu-1 were cultured in RPMI. 293T, U2OS, HCT116 p53+/+ and p53−/−,
and KrasLA/+; p53LSL/LSL; ROSA26CreERT2 cells (provided by D. Feldser) were maintained
in DMEM. For p53 restoration, KPR cells were treated with 250 nM hydroxytamoxifen (4-
OHT, Sigma) or vehicle control (ethanol). Transient transfections were performed using
Mirus with 2–10 μg DNA per 10 cm dish. For generating viral supernatants, 293T cells were
transfected with MSCV vectors, Gag/pol, and Env plasmids and supernatants were harvested
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after 48–72 hrs. Human cell lines were infected twice with retroviral supernatant at 1:1
(media: supernatant) with 1000× polybrene (8 μg/mL) and then selected for 2–3 days in
puromycin. Antibodies, constructs and reagents are provided in Supplemental Experimental
Procedures.
siRNA
siRNAs were obtained from Qiagen: AllStars negative siCONTROL (#1027286), human
CRADD/RAIDD #2 (SI00056035), LRDD/PIDD as published in (Tinel and Tschopp,
2004), Caspase-2 #10 (SI00299551) and #11 (SI02625546), and Caspase-3 #2 (SI00062937)
and #9 (SI03100041). U2OS cells were transfected with siRNAs (20 nM) in Opti-MEM
using Mirus TransIT-TKO transfection reagent according to manufacturer's instructions.
After 24 hrs, cells were damaged with doxorubicin and harvested after various time points
for western blot as described. For knockdown validation, cells were harvested 30 hrs after
transfection. RNA was isolated and subjected to real time RT-PCR as described in
Supplemental Experimental Procedures.
Western blotting
For nuclear and cytoplasmic fractionations, lysates were prepared as previously described
(Oliver et al., 2010). Protein samples were separated via SDS-PAGE and blotted to a PVDF
membrane. Membranes were blocked for 1 hr, followed by overnight incubation with
primary antibodies at 4°C. Membranes were washed 6 × 5 min at room temperature. HRP-
conjugated secondary antibodies (Jackson ImmunoResearch, 1:10,000) were incubated for 1
hr at room temperature. For detection, membranes were exposed to Western-Lightning ECL
(Perkin-Elmer) and detected on Kodak film. Blots were stripped and reprobed for PARP
and/or NEMO for nuclear and cytoplasmic controls, respectively.
Immunoprecipitations (IPs)
Cells were lysed on ice for 10 min in a buffer containing 0.1% NP-40, 5 mM EDTA, 50 mM
Tris pH 8.0, 150 mM NaCl, followed by three cycles of freezing and thawing. After
centrifugation (4C, 10 min, 16000 g), the supernatants were pre-cleared at 4C on a rotating
wheel for 45 min in the presence of 20 μl sepharose 6B (Sigma). After centrifugation (4C, 1
min, 1900 g), a small fraction of supernatant was frozen for later analysis (cell extract) and
the remaining fraction was incubated at 4C on a rotating wheel, overnight, in the presence of
10 μl sepharose 6B, 10 μl Protein G sepharose (GE Healthcare) and 0.5 μg of desired
antibody. The IPs bound to protein G were washed 3× in lysis buffer, prior to boiling in
sample buffer containing DTT for analysis by western blot.
For the Mdm2 cleavage assay, the washed Mdm2 IPs bound to protein G were incubated
with 0.5 units of recombinant caspase-2 or caspase-3 (Enzo Life Sciences, units specified by
manufacturer) in a buffer containing 0.1% CHAPS, 20 mM HEPES pH 7.2, 50 mM NaCl,
10 mM EDTA, 5% glycerol and 10 mM DTT. After 45 min incubation at 37C, samples were
boiled in sample buffer containing DTT for analysis by western blot.
In vitro caspase assay
For each reaction, 10 ng recombinant Mdm2 (Calbiochem, Cat #444146) was added to
buffer containing 0.1% CHAPS, 20 mM HEPES pH 7.2, 50 mM NaCl, 10 mM EDTA, 5%
glycerol and 10 mM DTT. Mdm2 was incubated alone or in the presence of increasing
amounts of recombinant caspase-2 or caspase-3 (0.02, 0.1 or 0.5 units, according to
manufacturer's instructions). The samples were incubated for 45 min at 37C and then
terminated by boiling in sample buffer containing DTT. Samples were then loaded on gels
for analysis by western blot.
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Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. PIDD positively regulates p53 levels
A) Pidd levels analyzed by real time RT-PCR and normalized to actin; fold change of 4OHT
relative to vehicle control. n = 3. B) Cell number measured in triplicate of PIDD-expressing
cells compared to control cells after 72hr, n = 2, except for H1299, n = 1. Average % cell
number for PIDD-expressing cells compared to control for p53 wild-type (66% +/− 5%) vs.
p53 null/mutant (100% +/− 5%). C) IC50 for PIDD vs. control cells following 48 hr
cisplatin. Average data from two independent sets of cells performed in triplicate. Cisplatin-
resistant p53 wild-type lines (n = 4 of 5) vs. p53 null/mutant lines (n = 0 of 4) (p < 0.01, Chi
Square and p < 0.04, Fisher's Exact). D) p53 wt or null HCT116 cells expressing PIDD or
vector. Cells counted in quadruplicate every 24 hrs, n = 2. For p53 wt cells, p < 0.02. E)
Immunoblot of nuclear/cytoplasmic (n/c) fractions in control or PIDD-expressing cells. p65
and PARP serve as cytoplasmic and nuclear loading controls, respectively. F) Fold change
in p21 and p53 mRNA levels in p53 wild-type (H460, SW1573, A549) and p53 mutant cells
(COR-L23, H1299) in PIDD-expressing vs. control cells. n = 3, normalized to ACTIN. Error
bars in all panels represent mean +/− SD. See also Figure S1.
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Figure 2. PIDD-induced growth arrest and cisplatin resistance depend on Caspase-2
A) Immunoblot for pro-Caspase-2 in p53 wild-type lines (top) with loading control in Fig.
1E; p53 null/mutant lines (bottom) with Nemo as cytoplasmic loading control. B) Caspase-2
levels analyzed by real time RT-PCR and normalized to actin, n = 3. C) Cell viability assays
performed with MSCV-control, PIDD, or PIDD point mutants (S446A, F582A, and S446A/
F582A) stably expressed in H460 cells, n = 3. IC50 presented in table (μM, cisplatin). D)
Immunoblot of n/c lysates from (C). Full-length (FL) and cleavage fragments of PIDD
indicated by arrowheads. E) Growth rate of A549 cells stably expressing control (MLH) or
Caspase-2 shRNAs (shC2) +/− PIDD. Performed in triplicate; n = 2. Error bars in all panels
represent mean +/− SD. See also Figure S2.
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Figure 3. The Caspase-2-PIDDosome promotes Mdm2 cleavage
A) Immunoblot of n/c lysates from control or PIDD-expressing NSCLC cell lines for Mdm2
expression. B) Sequence conservation of Mdm2 cleavage site, DVPD, among vertebrate
species. Conserved residues are highlighted. Bottom plot shows consensus residues and
degree of conservation at aligned sites. C) 293T cells transfected with eGFP control, myc-
tagged Mdm2 (WT), point mutant Mdm2 (D367A), (D367E) or truncated Mdm2 (p60). D)
Immunoblot of n/c fractions from 293T cells transiently expressing control or MSCV-PIDD
+/− myc-tagged Mdm2. E) Immunoblot of n/c fractions from 293T cells expressing control
or Flag-tagged RAIDD with wild-type (WT) or D367A Mdm2. F) Immunoblot of n/c
fractions from 293T cells expressing truncated HA-tagged active or inactive (C320A)
Caspase-2 with wild-type or D367A Mdm2. See also Figure S3.
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Figure 4. Caspase-2 cleaves Mdm2 in vitro
A) IPs from 239T cells expressing control (none), wild-type (WT) or D367A Mdm2
incubated +/− recombinant human Caspase-2 (C2) or Caspase-3 (C3). Immunoblot for
Mdm2 (N-terminal and C-terminal antibodies) with full-length (FL) and cleavage fragments
indicated by arrows. B) Immunoblot for Mdm2 (C-terminal) from recombinant Mdm2
incubated +/− 5-fold serial dilutions (black arrows) in the presence or absence (ctrl) of
recombinant Caspase-2 (C2) or Caspase-3 (C3). C) Immunoblot of n/c fractions from 293T
cells transiently expressing myc-tagged Mdm2 +/− MSCV-shCasp2. Mdm2 p60 fragments
indicated by double arrowheads. D) Immunoblot of n/c fractions from A549 cells stably-
expressing MSCV-shCasp2 or vector control. Parp/Nemo immunoblots for n/c loading
controls, respectively. E) Immunoblot of n/c lysates from A549 cells +/− vector (MLH) or
shC2, +/− PIDD or vector control.
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Figure 5. Cleaved Mdm2 binds p53 and promotes p53 stabilization
A) Left panel: Immunoblot of total extracts from control or PIDD-expressing A549 cells.
Right panel: Control or p53 IPs blotted for Mdm2 (C-terminal and N-terminal) or p53. Star
(*) indicates non-specific band. B) Immunoblot of n/c fractions from 293T cells transiently
expressing control, wild-type (WT), point mutant (D367A), truncated Mdm2 (p60), or
indicated combinations. Bracket indicates p53 modifications. C) Same as in B, except in
U2OS cells. D) Immunoblot of n/c fractions from 293T cells transiently expressing
truncated active (Casp2) or catalytically-dead (C320A) Caspase-2 +/− Mdm2. See also
Figure S4.
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Figure 6. Caspase-2-PIDDosome cleaves Mdm2 in response to DNA damage
A) Immunoblot with cytoplasmic fractions from A549 cells treated with vehicle, 0.1 or 0.5
μM doxorubicin (Dox) +/− MSCV-shCasp2 (shC2). B) Same as in A, except in U2OS cells.
C&D) Real time RT-PCR for human PIDD (C) or RAIDD (D) normalized to ACTIN, and
relative to siRNA controls. Error bars represent mean +/− SD. E) Immunoblot of
cytoplasmic lysates from U2OS cells treated +/− 500 nM Dox for 24 hrs. Nemo and pro-
Casp3 immunoblot (controls). F) Same as in E with total cell lysates, with siRNAs to control
(ctrl), Caspase-2 (siC2), or two different siRNAs to Caspase-3 (siC3, siC3'). See also Figure
S5.
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Figure 7. The Caspase-2-PIDDosome regulates p53 dynamics in response to DNA damage
A) Immunoblot with total lysates from U2OS cells transfected with siControl (siCON) vs.
siCaspase-2 (left panel) or siPidd (right panel) treated with 0.5 μM Dox and harvested after
indicated hrs. B) Same as in A, except cells were washed after 8 hrs damage and analyzed at
later time points. C) Quantitation of p53 levels relative to ACTIN in panel B. D) Apoptotic/
dead cells measured by flow cytometry for Annexin-V in U2OS cells expressing siCON or
siPidd cells treated +/− Dox. Error bars represent mean +/− SD. E) Model of p53-induced
positive feedback loop. Activation of p53 (here, via DNA damage) induces expression of the
p53 target gene, PIDD. Increased PIDD expression promotes Caspase-2-PIDDosome
formation, leading to activation of Caspase-2 as previously shown. Full-length Mdm2, an E3
ubiquitin ligase, can promote ubiquitination and degradation of p53 (unstable p53, light
blue). Activated Caspase-2 cleaves Mdm2 at amino acids DVPD, separating the N-terminal
p53-binding domain from the RING domain. Cleaved Mdm2 can bind p53 but cannot
promote its degradation (stabilized p53, dark blue)—ultimately reinforcing p53 levels in a
positive feedback loop. See also Figure S6.
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